Puresafe Water Systems, Inc.

Era-massis, Inc.

Gil Tenne

Mark L Levitt

Anahit Karapetian

Systems and methods for versatile water purification. The methods may include floating a raft on a source of water to be purified. The raft may provide inlet for the water. The methods may include pumping the water and selectively pre-treating the pumped water by chemical injection prior to filtration. The methods may include passing the pumped water, sequentially, through a multi media filter to produce filtered water, into a plurality of reverse osmosis columns to produce osmosis water, and into a buffer tank. The methods may include injecting ozone into water pumped from the tank, and selectively returning the ozone-injected water to the tank via a first valve. Via a second valve, the ozone-injected water may be passed to a bottle washing station for washing and sterilization of receptacles to receive purified waters pumped from the tank. Methods may include Ultra Violet and chemical treatment of water prior to dispensing.

Versatile water purification systems and methods

The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI). Further, the method of the invention is based on determining level of expression or level of activity of L-PAR II in a fecal-derived microorganism/s sample, the level determined being also indicative of the presence or absence of cancer cells in the subject from which the fecal sample was derived.

Growing community of inventors

Shoham, Israel

Gil Tenne